leisure time -WSS

leisure time

author：focus 2025-09-30 00:39:35 - browse：749

Three boxes of Wegovy stands in a line — coverage from STAT — Steffen Trumpf/picture alliance/Getty Images

WASHINGTON — Novo Nordisk’s newly won permission to market the heart benefits of its obesity drug Wegovy could provide a backdoor way to expand access to the drug for people on Medicare, experts told STAT.

Currently, Medicare is prohibited by law from covering medications for obesity treatment alone. While companies that manufacture wildly popular anti-obesity medications and their allies haven’t been successful in lobbying Congress to change the law, the Food and Drug Administration’s move could give doctors an avenue to prescribe the medications to some Medicare patients.

Wegovy’s new label indicates that the drug can be used to reduce the risk of major heart complications for people who are overweight or obese and have existing heart disease, Novo said in a statement Friday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Republicans love RFK Jr. What's that tell us about health in 2024?

WSS

How the first Native Hawaiian psychiatrist helped diversify medicine

U.K. sequencing study surfaces new findings about tumor DNA

Former Pear Therapeutics executives start new VC firm

Federal weight loss drug coverage is 30 years out of date

Republicans love RFK Jr. What's that tell us about health in 2024?

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

explore

leisure time

explore

Sports medicine is finally prioritizing gender equality

AdventHealth escalates lawsuit against insurance vendor Multiplan

Walensky prepares to leave CDC — and Congress — behind

Kellogg’s is going to war over Mexico’s nutrition label rules

Tori Bowie and the unacceptable rates of Black maternal death

3 trends to watch in health tech's hiring outlook for 2024

Hepatitis C has a cure — but many Americans still lack access to it

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

BioMarin wins approval for gene therapy to treat hemophilia A

AdventHealth escalates lawsuit against insurance vendor Multiplan

explore

Antibiotic resistance and the global rise in human conflict

Why psychiatrists like me stop taking insurance

Burning questions for the 2024 JPM Healthcare Conference

As obesity drug market grows, telehealth companies court payers

As obesity drug market grows, telehealth companies court payers

JPM: CVS says Medicare Advantage patients are impacting profits

knowledge

entertainment

focus

focus